Overview

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
Participant gender:
Summary
The study is investigating the ability of UroGen's UGN-101 to treat urothelial carcinoma tumors from the upper urinary tract.
Phase:
Phase 3
Details
Lead Sponsor:
UroGen Pharma Ltd.
Treatments:
Mitomycin
Mitomycins